Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT with Atezolizumab and Bevacizumab in Advanced HCC with Major PVTT
NCT06823375Phase 2Recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoint: 1-year Overall Survival. Started Jul 2025; status: recruiting.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06823375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06823375.